The upregulation of SIGLEC15 was linked to longer overall survival in bladder urothelial carcinoma, breast invasive carcinoma, head and neck squamous cell carcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma, and longer relapse-free survival in breast invasive carcinoma, liver hepatocellular carcinoma, ovarian serous cystadenocarcinoma, and uterine corpus endometrial carcinoma (27). This evidence concerns the gene SIGLEC15 and ovarian serous cystadenocarcinoma.